Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a median overall survival of 34.3 months with the combination, compared to 27.9 months with chemotherapy alone, nearly doubling historical survival rates. This dual-targeting treatment addresses a patient group with limited options and poor prognosis, marking a major advance in lung cancer therapy. The results support RYBREVANT's role as a first-line treatment and ongoing research aims to improve patient experience and outcomes further.
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's d...
As of October 2026, U.S. Treasury bills yield between 3.98% and 4.44% depending on maturity, surpassing Johnson & Johnson's 2.05% dividend yield. Treasury bills guarantee fixed returns until maturity but carry reinvestment and inflation risks, while ...
Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong per...
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
